Lataa...
A double-blind, placebo-controlled, single ascending-dose study of remyelinating antibody rHIgM22 in people with multiple sclerosis
OBJECTIVE: The objective of this paper is to assess, in individuals with clinically stable multiple sclerosis (MS), the safety, tolerability, pharmacokinetics (PK) and exploratory pharmacodynamics of the monoclonal recombinant human antibody IgM22 (rHIgM22). METHODS: Seventy-two adults with stable M...
Tallennettuna:
| Julkaisussa: | Mult Scler J Exp Transl Clin |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
SAGE Publications
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5768281/ https://ncbi.nlm.nih.gov/pubmed/29348926 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2055217317743097 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|